

Wild-Type Phages for Drug-Resistant *P. aeruginosa* Infections

Research Team

- Researcher: Kotaro Kiga
- Affiliation: Department of Drug Development
- Team: Tomofumi Kawaguchi, Kotaro Chihara, Shinjiro Ojima et al.
- Target: **Drug-resistant *P. aeruginosa* infections**
- Development stage: Basic research


Research Concept & Technology

- **Development candidate: Wild-type phages**
- Collect and select wild-type phages active against drug-resistant *P. aeruginosa* and evaluate them as therapeutic candidates
- Evaluate phage cocktails and combination therapies based on host range, bactericidal activity, and the risk of resistance development
- Assess phage monotherapy and phage–antibiotic combinations for biofilm-associated and chronic infections

Background & Unmet Need

- *P. aeruginosa* causes healthcare-associated and chronic infections; antimicrobial resistance further complicates treatment
- Biofilm formation and host factors often make these infections difficult to treat
- Therapies that do not rely solely on existing antibiotics, or that complement them, are needed

Project Overview



Development Plan

- Expand the clinical isolate panel and phage library
- Define quality, safety, and dosing strategies for lead phages